Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluarix Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Influenza Vaccination in the Emergency Department

NCT00822627
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination, Education and referral
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
6 Months and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00952276
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Anaheim, California • Fountain Valley, California • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 20, 2026, 5:57 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

NCT05869968
View directory record Official record
Conditions
Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine, COVID-19 Vaccine
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874
View directory record Official record
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Quadrivalent Influenza Vaccine Among Adults

NCT01218646
View directory record Official record
Conditions
Influenza
Interventions
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
12
States / cities
Hoover, Alabama • South Miami, Florida • Springfield, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Altruism to Enhance Vaccine Acceptance

NCT04568590
View directory record Official record
Conditions
Vaccine Refusal
Interventions
educational intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Anti-Influenza Immune Plasma, Standard Care
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
35
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT00755703
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
Pandemic Influenza Vaccine, Placebo
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

NCT01142362
View directory record Official record
Conditions
Healthy
Interventions
VGX-3400X
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 20, 2026, 5:57 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

NCT05518500
View directory record Official record
Conditions
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions
Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4)
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

NCT00253734
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (IM), Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

NCT00772109
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
4,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
46
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

NCT01215734
View directory record Official record
Conditions
Adult Stem Cell Hematopoetic Transplant
Interventions
High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine
Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children

NCT00446628
View directory record Official record
Conditions
Influenza
Interventions
behaviors reducing spread of influenza
Behavioral
Lead sponsor
Kiren Mitruka
Federal
Eligibility
6 Months and older
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00347672
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 20, 2026, 5:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Rapid Vaccination of Hard-To-Reach Populations

NCT00155974
View directory record Official record
Conditions
Influenza
Interventions
Community-based vaccine outreach intervention
Biological
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 20, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350
View directory record Official record
Conditions
Healthy Adults
Interventions
LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
Device · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 20, 2026, 5:57 AM EDT